eBioscience, an Affymetrix (Nasdaq:AFFX) business, announces the availability of PrimeFlow™ RNA Assay, the first and only flow cytometry assay capable of simultaneous detection of RNA and protein within millions of cells at single-cell resolution. Current flow cytometry applications are limited to antibody-based interrogation of cell surface and intracellular proteins. With the novel PrimeFlow assay, researchers can now incorporate the simultaneous analysis of RNA transcripts and proteins to elevate their understanding of single-cell dynamics. "Single-cell analysis is a rapidly growing field in biomedical research that yields an unprecedented level of information," said Filippos Porichis, PhD, Director of the Ragon Institute of MGH, MIT and Harvard's International Programs and first author of a newly published Nature Communications paper citing the use of RNA transcript with flow cytometry. "PrimeFlow RNA Assay enables high throughput detection of RNA and protein expression; therefore, it can be used to characterize, mechanistically and phenotypically, co-expression of RNAs with the functional proteins at the single-cell level. This assay, with a user-friendly protocol that has many similarities with standard antibody-staining procedures and data acquisition of flow cytometry, is an invaluable tool for any immunology lab performing translational research." "The major advantage of this technology is the ability to detect, with high sensitivity, mRNAs for which flow cytometry antibodies against the corresponding proteins perform poorly or are not available," adds Dr. Daniel Kaufmann, Research and Clinical Associate Professor, Dept. of Medicine, University of Montreal. "Furthermore, the capability to directly measure non-coding RNAs, whose critical functional roles are increasingly recognized, in a heterogeneous cell population has vast potential applications in cell biology." "Single-cell gene expression assays, such as PrimeFlow RNA Assay, showcase one of the many exciting opportunities we have for integrating cell analysis and genomics, which open up new avenues for innovation and growth," said Frank Witney, CEO and President of Affymetrix. "PrimeFlow RNA Assay represents the capabilities and expertise of eBioscience and Affymetrix brought together to enable the scientific community to advance the understanding and application of biology for a better world."
To further discuss potential applications of PrimeFlow RNA Assay, please email us at MarketingDept@ebioscience.com.PLEASE NOTE: eBioscience and PrimeFlow are trademarks of eBioscience, Inc., and Affymetrix and the Affymetrix logo are trademarks of Affymetrix, Inc. All other trademarks and product names are the property of their respective owners. About Affymetrix Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 65,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com. Forward-looking statements All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2013, and other SEC reports for subsequent quarterly periods.